相关实验视频

Updated: May 1, 2026

Rapid and Low-cost Prototyping of Medical Devices Using 3D Printed Molds for Liquid Injection Molding

Rapid and Low-cost Prototyping of Medical Devices Using 3D Printed Molds for Liquid Injection Molding

Published on: June 27, 2014

用SeDeM和Powder流动工具协助设计用于抗真菌治疗的卢利可纳固体SMEDDS

Sharad S Kale¹, Deepak Kulkarni², Anuja G Magar³

¹Department of Physiology, School of Medicine, Pusan National University, Yangsan, Republic of Korea.

Therapeutic delivery

|February 28, 2026

概括

这项研究开发了一种固体的自我微乳化药物输送系统 (S-SMEDDS),以改善卢利可纳.

科学领域:

制药科学制药科学
药物输送系统药物输送系统
皮肤病学皮肤病学

背景情况:

卢利可纳是一种广泛的抗真菌药物,具有较差的溶解性和皮肤透性,限制了其局部疗效.
现有的配方在实现真菌感染的最佳治疗结果方面面临挑战.

研究的目的:

开发一种固体的自我微乳化药物输送系统 (S-SMEDDS) 用于卢利可纳.
为了提高luliconazole的可溶性,通过皮肤传递,以及局部应用的配方稳定性.

主要方法:

使用SeDesM工具优化了液体自我微乳化药物输送系统 (SMEDDS).
优化的液体SMEDDS通过吸附在Neusilin® US2和小麦上被转化为固体.
配方被评估为体外药物释放,通过皮肤透和抗真菌活性.

主要成果:

开发的固体SMEDDS表现出更好的流动性能.
对于S-SMEDDS,观察到增强的ex vivo药物释放和通过皮肤透.
该S-SMEDDS证明了强大的抗真菌活性对白 Candida,但对黑色 Aspergillus 有限的有效性.

结论:

在S-SMEDDS平台成功地改善了luliconazole的可溶性,通过皮肤传递和稳定性.
这种方法为治疗真菌感染提供了一种安全,有效和可扩展的局部配方.
该S-SMEDDS代表了工业规模生产增强抗真菌配方的实用途径.

关键词:

纽西林 (Neusilin) US2 美国这里是SMEDDS.这是一种抗真菌药物.卢利可纳醇是一种小麦草小麦草

更多相关视频

Microfluidic Tools for Probing Fungal-Microbial Interactions at the Cellular Level

Microfluidic Tools for Probing Fungal-Microbial Interactions at the Cellular Level

Published on: June 23, 2022

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

相关概念视频

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

Antifungal Agents

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...